ImmunoGen (NASDAQ:IMGN) is a clinical stage biotech company that is focused on cancer therapeutics. It has developed an antibody-drug conjugate or “ADC” technology which is already being used in an approved and marketed product and is also being developed for use in a few other clinical stage candidates that are part of ImmunoGen’s current pipeline. The lead pipeline candidate for this company is called “Mirvetuximab Soravtansine”. This will be tested as an ovarian cancer treatment in Phase 3 trials which are expected to commence very soon. Obviously, this company has faced some setbacks in 2016, and that, along with tax loss selling pressure, is why the stock is trading for less than $2 per share. However, as seasoned investors know, setbacks can create significant buying opportunities, especially when it pertains to the biotech sector. Clinical stage biotech companies and their stocks are fueled by hope and cash and ImmunoGen has both of these. I believe there is a strategic opportunity for investors who buy this stock now, because it appears ripe for a potential “January Effect” rally as tax loss selling ends soon. It also appears poised for a short squeeze rally in the very near term. Furthermore, this stock appears to have longer term upside due to a number of high potential pipeline candidates and partnership deals with a few leading pharmaceutical and biotech giants. Let’s take a closer look at the potential downside risks (which I believe are very limited at this time) as well as a number of reasons why this stock is a strong buy now:
Top Biotech Stocks To Invest In 2018: Halliburton Company(HAL)
- [By Chris Lange]
Haliburton Co. (NYSE: HAL) is expected to reveal its fourth-quarter results on Monday. The consensus forecast calls for $0.46 in EPS, as well as $5.63 billion in revenue. Shares were trading at $53.01 on Fridays close. The consensus price target is $55.09. The stock has a 52-week range of $38.18 to $58.78.
- [By Tyler Crowe]
2016 was an interesting year for Halliburton (NYSE:HAL). Not only did the oil-field services company work through one of the largest downturns in the history of oil and gas, but it also had to deal with the financial fallout from a major acquisition blowing up in its face. When it reported fourth-quarter and fiscal 2016 earnings this week, the company showed that it had taken a big blow, but was ready to move on to the next big thing in the oil and gas market. Let’s take a quick look at the company’s results for the year that was, and see what could be in store in the coming quarters.
- [By Ben Levisohn]
When Weatherford International (WFT) announced that it had named Halliburton (HAL) CFO Mark McCollumits new CEO, its shares jumped as some observers contended itincreased the odds of an acquisition by the oil-services giant. It looks like they picked the wrong oil-services giant, however, as Weatherford and Schlumberger (SLB) announced a joint venture late Friday, one that has sent Weatherford’s shares soaring and earned it an upgrade from Wells Fargo analystsJudson Bailey andColeman Sullivan. They explain why:
Top Biotech Stocks To Invest In 2018: Laredo Petroleum, Inc.(LPI)
- [By Ben Levisohn]
After a rally for the ages, the price of oil is back over $50. But the biggest threat to oil might be more production from exploration & production companies drilling in the U.S. shale, say Credit Suisse analyst Mark Lear and team, who cut their ratings on Carrizo Oil & Gas (CRZO), Laredo Petroleum (LPI) and Sanchez Energy (SN). They explain why:
Top Biotech Stocks To Invest In 2018: Akorn, Inc.(AKRX)
- [By Lisa Levin]
In trading on Friday, healthcare shares fell by 0.62 percent. Meanwhile, top losers in the sector included Akorn, Inc. (NASDAQ: AKRX), down 17 percent, and BioDelivery Sciences International, Inc. (NASDAQ: BDSI), down 14 percent.
- [By Ben Levisohn]
Shares of Endo International (ENDP) have tumbled 40% today after it said profits would fall well short of analyst expectations thanks, in part, to plunging generic drug prices. Leerink’s Jason Gerberry and team look for specialty pharmaceutical companies that have similar business models–and find Akorn (AKRX), Perrigo (PRGO), and Teva Pharmaceutical Industries (TEVA). They explain:
- [By Wayne Duggan]
Akorn, Inc. (NASDAQ: AKRX) shares are drifting higher by 0.27 percent (about $0.10 per share) Wednesday after jumping 3.2 percent Tuesday following a report the company was on the verge of a buyout deal.
- [By Dan Caplinger]
Despite a lack of conviction in the market at large, some stocks posted sharp gains on Friday, and Diana Shipping (NYSE:DSX), Akorn (NASDAQ:AKRX), and Granite Construction (NYSE:GVA) were among the best performers on the day. Below, we’ll look more closely at these stocks to tell you why they did so well.
- [By Alex McGuire]
As a service to our readers, the following list provides the 10 top pharmaceutical stocks to watch this month (May 2017), including the biggest gainers from April…
Pharmaceutical Stock Current Share Price April 2017 Gain
Cleveland BioLabs Inc. (Nasdaq: CBLI) $3.62 +120.6%
Nexvet Biopharma Plc. (Nasdaq: NVET) $6.61 +69.7%
Motif Bio Plc. (Nasdaq ADR: MTFB) $10.10 +68.2%
Axovant Sciences Ltd. (NYSE: AXON) $24.43 +62.3%
Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC) $5.49 +46.7%
Conatus Pharmaceuticals Inc. (Nasdaq: CNAT) $8.67 +44.9%
Akebia Therapeutics Inc. (Nasdaq: AKBA) $13.07 +43.3%
Akorn Inc. (Nasdaq: AKRX) $33.28 +38.9%
Rockwell Medical Inc. (Nasdaq: RMTI) $8.78 +37.4%
Akari Therapeutics Plc. (Nasdaq ADR: AKTX) $15.02 +35.4%
The best-performing pharma stock of the month – Cleveland BioLabs Inc. – surged 120.6% to $3.53 a share by April 28. That crushed both the Nasdaq Biotech Index’s 1.5% gain and the Dow Jones’ 1.3% rise over the same period.
- [By Paul Ausick]
Akorn Inc. (NASDAQ: AKRX) dropped nearly 40% Tuesday to post a new 52-week low of $18.20. Shares closed at $30.28 on Monday and the stock’s 52-week high is $34.00. Volume was nearly 22 million, more than 20 times the daily average. A potential acquirer has announced an investigation into possible data breaches. https://247wallst.com/healthcare-business/2018/02/27/could-data-breaches-break-up-the-akorn-aquisition/